Last reviewed · How we verify
Canagliflozin - SGLT2i
Canagliflozin blocks the SGLT2 transporter in the kidney to reduce glucose reabsorption, allowing excess glucose to be excreted in urine and lowering blood sugar.
Canagliflozin blocks the SGLT2 transporter in the kidney to reduce glucose reabsorption, allowing excess glucose to be excreted in urine and lowering blood sugar. Used for Type 2 diabetes mellitus, Reduction of cardiovascular death and hospitalization for heart failure in patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors.
At a glance
| Generic name | Canagliflozin - SGLT2i |
|---|---|
| Also known as | Invokana |
| Sponsor | Royal Devon and Exeter NHS Foundation Trust |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 (sodium-glucose cotransporter 2) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
SGLT2 (sodium-glucose cotransporter 2) is responsible for reabsorbing filtered glucose back into the bloodstream in the proximal tubule of the kidney. By inhibiting this transporter, canagliflozin prevents glucose reabsorption, causing increased urinary glucose excretion (glycosuria) and a net reduction in blood glucose levels. This mechanism is insulin-independent and also promotes modest natriuresis and weight loss.
Approved indications
- Type 2 diabetes mellitus
- Reduction of cardiovascular death and hospitalization for heart failure in patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Polyuria/polydipsia
- Hypotension
- Diabetic ketoacidosis (rare)
Key clinical trials
- Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors
- Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists (PHASE4)
- The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease (PHASE2)
- Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes (PHASE4)
- Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer (PHASE2)
- Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Canagliflozin - SGLT2i CI brief — competitive landscape report
- Canagliflozin - SGLT2i updates RSS · CI watch RSS
- Royal Devon and Exeter NHS Foundation Trust portfolio CI